Pharmaron Beijing Co., Ltd. Class H (HK:3759) has released an update.
Pharmaron Beijing Co., Ltd. reports a mixed financial outlook for the first half of 2024, with net profit attributable to owners of the parent increasing by 34%-45% year-on-year, despite a slight revenue decline of 0%-3%. The company experienced a decrease in both net profit excluding non-recurring gains or losses and non-IFRS adjusted net profit by 36%-41% and 23%-28%, respectively. Significant non-recurring gains included the sale of equity interests in PROTEOLOGIX following its acquisition by Johnson & Johnson, contributing approximately RMB 560 million to the interim results.
For further insights into HK:3759 stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
Questions or Comments about the article? Write to editor@tipranks.com